Can Teva Turn Things Around?
Sep 17th 2013 10:59PM
Updated Sep 17th 2013 11:00PM
Shares of the largest generic drug company in the world, Teva Pharmaceuticals , are down more than 7.5% in the last 12 months. This drop largely has to do with fears that biosimilars of the multiple sclerosis drug Copaxone, which currently accounts for a fifth of Teva's top line, may enter the market in the next couple of years. But what growth opportunities does the company have in the future, and what moves can it make to boost investor confidence? Analysts David Williamson and Max Macaluso discuss this topic in this segment from the Motley Fool's health-care show Market Checkup.
Looking for more dividend ideas?
One of the best parts of owning some big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report, "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
The article Can Teva Turn Things Around? originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.